SoftBank Investment Advisers contributed to a round for the cancer and immune disorder drug developer co-led by Logos Capital and Boxer Capital.
US-based precision medicine developer Vividion Therapeutics closed a $135m series C round today that included SoftBank Investment Advisers, which manages telecommunications and internet group SoftBank’s Vision Funds.
Logos Capital and Boxer Capital co-led the round, which included Avoro Capital Advisors, RA Capital Management, Surveyor Capital, Woodline Partners, Acuta Capital, Driehaus Capital Management, funds and accounts managed by BlackRock and funds and accounts advised by T Rowe Price.
Existing investors Arch Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest…
